



Welcome to this special edition of *AOT: The Management of Thyroid Tumors in 2021 and Beyond!*

It has been our honor to collaborate with a renowned group of expert thyroid surgeons, clinicians, and thought leaders across the world to bring you this special edition of *Annals of Thyroid; The Management of Thyroid Tumors in 2021 and Beyond*. In this journal we have attempted to bring some of the most exciting (and controversial!) topics in head and neck endocrine surgery together for your review. We have divided this edition into three general sections: Current and Emerging Therapies, Remote-Access Surgery, and Computer and Technology Innovations. Within each section we have recruited those experts who are passionate about their particular topic to teach us where the field currently is and what the future holds.

Although the pandemic has put a temporary pause on meeting in person and sharing state-of-the-art knowledge together, we hope you find this special edition as the next best thing. We have been fortunate to work with a group of talented physicians whose collegiality and professionalism speak loudly to the bright future of head and neck endocrine surgery. We hope you enjoy!

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, *Annals of Thyroid* for the series “The Management of Thyroid Tumors in 2021 and Beyond”. The article did not undergo external peer review.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at <http://dx.doi.org/10.21037/aot-21-14>). The series “The Management of Thyroid Tumors in 2021 and Beyond” was commissioned by the editorial office without any funding or sponsorship. JDR and JOR served as the unpaid Guest Editors of the series. JDR serves as an unpaid editorial board member of *Annals of Thyroid* from Jul 2019 to Jun 2021 and served as co-chair on Endocrine Tech Committee for the American Head and Neck Society. Dr. JOR reports consulting fees from Baxter scientific and personal payment from Independent contracts, which do not directly relate to the submitted manuscript. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.



Jeremy D. Richmon



Jonathon O. Russell

Jeremy D. Richmon, MD, FACS

Associate Professor; Mass Eye and Ear, Harvard University, Boston, MA, USA. (jeremy_richmon@meei.harvard.edu)

Jonathon O. Russell, MD, FACS

Associate Professor; Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University, Baltimore, MD, USA.

(jrusse41@jhmi.edu)

Received: 19 April 2020; Accepted: 14 May 2021; Published: 30 June 2021.

doi: 10.21037/aot-21-14

View this article at: <http://dx.doi.org/10.21037/aot-21-14>

doi: 10.21037/aot-21-14

Cite this article as: Richmon JD, Russell JO. Welcome to this special edition of *AOT: The Management of Thyroid Tumors in 2021 and Beyond!* *Ann Thyroid* 2021;6:8.